2013 Sales of Recombinant Therapeutic Antibodies & Proteins
Delivery costs do not apply or are included.
Ask a question about this product
2013 Sales of Recombinant Therapeutic Antibodies & Proteins
This Competitive Intelligence report prepared by La Merie Business Intelligence provides a compilation of the sales data of recombinant therapeutic proteins and antibodies in the calendar year 2013. Sales data were obtained from company publications and refer to branded products originating from companies based in regulated markets. All sales data were converted from their original, published currency into US$. Sales figures represent the sum of revenues in all territories where the products are marketed and may be presented either at continuous exchange rates or after hedging.
Sales data are presented for each product within the respective class of biologics. The data were analyzed to establish a ranking list of blockbuster biologics with 2013 sales higher than US$ 1 bln. Another ranking list was prepared for companies according to biologics sales in 2013 and the percentage of antibody sales vs protein sales.
2013 Sales of Recombinant Therapeutic Antibodies & Proteins
Table of Contents
- 2013 Biologics Sales per Class of Products
- Blockbuster Biologics in 2013 (by generic name)
- Company Ranking List for Biologics Sales 2013
- Biologic Product Sales 2013
- Anti-TNF Antibodies
- Cancer Antibodies
- Insulin and Insulin Analogs
- Anti-Inflammatory and Anti-Autoimmune Antibodies
- Recombinant Coagulation Factors
- Interferon beta
- Erythropoietins
- G-CSF
- Ophthalmic Antibodies
- Enzyme Replacement Proteins
- Human Growth Hormone
- Interferon alpha
- Follicle Stimulating Hormone
- Antiviral Antibody
- Other Antibodies
- Other Proteins